Wanpen Vongpatanasin(@DrWanpen) 's Twitter Profileg
Wanpen Vongpatanasin

@DrWanpen

Hypertension Specialist, Cardiologist, Chulalongkorn University, Professor @UTSWheart, Hypertension Fellowship Director, @CircAHA, #AANHPIequity, Tweet all mine

ID:1059226077233582080

calendar_today04-11-2018 23:29:11

2,5K Tweets

1,2K Followers

929 Following

Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦(@DrMarthaGulati) 's Twitter Profile Photo

Our Statement AHA Science Circulation
Patient-Centered Adult CV Care
🏥Patient-centered care: main tenet of contemporary healthcare
🤝Can improve health equity & outcomes
🫀CV professionals should incorporate patient-centered care strategies routinely
📎shorturl.at/wRUY6

Our Statement @AHAScience @CircAHA Patient-Centered Adult CV Care 🏥Patient-centered care: main tenet of contemporary healthcare 🤝Can improve health equity & outcomes 🫀CV professionals should incorporate patient-centered care strategies routinely 📎shorturl.at/wRUY6
account_circle
Stephen Juraschek MD, PhD, FAHA, AHSCP-CHS(@spjuraschek) 's Twitter Profile Photo

Cool meta-analysis on long-term benefits of sodium substitution! Huge need for more trials in a more diverse range of cultural settings like the US. acpjournals.org/doi/10.7326/M2…

Thanks Mingyu Zhang, PhD, MHS for sharing the article with me!

account_circle
Swapnil Hiremath @hswapnil@bsky.social(@hswapnil) 's Twitter Profile Photo

Check out the recording of the excellent discussion around estimating GFR from Pierre Delanaye

CKD-EPI, EKFC, Iohexol clearance or Cystatin C?

youtu.be/2gScckBmFDw

account_circle
Circulation(@CircAHA) 's Twitter Profile Photo

SGLT2i Trialists Consortium: primary benefit of SGLT2i for MACE driven by reduction in CV death, without clear effect on myocardial infarction or stroke Sid M. Patel TIMI Study Group ahajournals.org/doi/10.1161/CI…

#CircACC24 #SimPub SGLT2i Trialists Consortium: primary benefit of SGLT2i for MACE driven by reduction in CV death, without clear effect on myocardial infarction or stroke @SidPatelMD @TIMIStudyGroup #AHAJournals ahajournals.org/doi/10.1161/CI…
account_circle
Nicolas Renna, MD PhD ISHF FESC(@nicolasrennamd) 's Twitter Profile Photo

KARDIA2 in : one single dosis zilebesiran 600mg. Add-on antihypertensive treatment in patient with uncontrolled hypertension was associated with increased risk of adverse effects. The results support the potencial biannual dosis of zib 600.

#LBCT KARDIA2 in #ACC24: one single dosis zilebesiran 600mg. Add-on antihypertensive treatment in patient with uncontrolled hypertension was associated with increased risk of adverse effects. The results support the potencial biannual dosis of zib 600.
account_circle
Nicolas Renna, MD PhD ISHF FESC(@nicolasrennamd) 's Twitter Profile Photo

Kardia 1 trial in : efficacy and safety of zilebesiran in patient with hypertension. Key point: plasma renin concentration(PRC) and race. Everything indicates that renin concentrations will be key for the upcoming studies on hypertension: Bax-HTN, Target-HTN and Kardia 3

Kardia 1 trial in #ACC24 : efficacy and safety of zilebesiran in patient with hypertension. Key point: plasma renin concentration(PRC) and race. Everything indicates that renin concentrations will be key for the upcoming studies on hypertension: Bax-HTN, Target-HTN and Kardia 3
account_circle
Ph.Gabriel Steg(@gabrielsteg) 's Twitter Profile Photo

Routine Beta-Blockers in Secondary Prevention — On Injured Reserve | New England Journal of Medicine nejm.org/doi/full/10.10…

account_circle
Wanpen Vongpatanasin(@DrWanpen) 's Twitter Profile Photo

Interesting results from KARDIA2 that show relatively modest reduction in 24ABP when added on top of olmesartan relative to indapamide or amlodipine. This seems to be similar to less effective BP lowering of duo ACEI-ARB or DRI-ARB.

Interesting results from KARDIA2 that show relatively modest reduction in 24ABP when added on top of olmesartan relative to indapamide or amlodipine. This seems to be similar to less effective BP lowering of duo ACEI-ARB or DRI-ARB.
account_circle
Rachel Skow, PhD(@RachelSkow) 's Twitter Profile Photo

Congrats to the NCAR award winners! Particularly my friends/colleagues Chris Hearon Jr. & Claire Kissell (née Trotter) 😀

Claire's poster is this evening [Saturday, P360] if you missed her talk, and Denis Wakeham is presenting some of the work with Chris at his poster [P344] today too!

account_circle
Eugene Yang(@DrEugeneYang) 's Twitter Profile Photo

Please join us this evening for this outstanding clinical spotlight session with hypertension experts. Learn about new therapies to treat resistant hypertension. American College of Cardiology

Please join us this evening for this outstanding clinical spotlight session with hypertension experts. Learn about new therapies to treat resistant hypertension. @ACCinTouch #ACC24
account_circle
C. Michael Gibson MD(@CMichaelGibson) 's Twitter Profile Photo

AEGIS-II trial shows in AMI pts with multivessel disease + additional CV risk factors and on GDMT, 4 weekly infusions of CSL112 did not reduce primary endpoint of CV death, MI, or stroke thru 90 days. Additional analysis shows CV outcome benefits statistically significant in pts…

AEGIS-II trial shows in AMI pts with multivessel disease + additional CV risk factors and on GDMT, 4 weekly infusions of CSL112 did not reduce primary endpoint of CV death, MI, or stroke thru 90 days. Additional analysis shows CV outcome benefits statistically significant in pts…
account_circle
APAC(@APAC_Cardiology) 's Twitter Profile Photo

Check out this recent publication from John Giacona, PhD, PA-C🫀, PhD, PA-C, CHC, 'HDL-C and Apolipoprotein A-I are Independently Associated with Skeletal Muscle Mitochondrial Function in Healthy Humans' at bit.ly/48QJnND 📰

Check out this recent publication from @GiaconaJohn, PhD, PA-C, CHC, 'HDL-C and Apolipoprotein A-I are Independently Associated with Skeletal Muscle Mitochondrial Function in Healthy Humans' at bit.ly/48QJnND 📰
account_circle
Stephen Juraschek MD, PhD, FAHA, AHSCP-CHS(@spjuraschek) 's Twitter Profile Photo

Interesting long-term follow-up data from ASCOT.

Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial academic.oup.com/eurheartj/arti…

account_circle
Prof Kamlesh Khunti(@kamleshkhunti) 's Twitter Profile Photo

RCT

Empagliflozin effective in ⬇️ liver fat in people with and without T2 diabetes.

⬇️ in liver fat content is independent of the ⬇️ in plasma glucose

Strongly associated with ⬇️ in body weight & improvement in insulin sensitivity

diabetesjournals.org/care/article-a…

RCT Empagliflozin effective in ⬇️ liver fat in people with and without T2 diabetes. ⬇️ in liver fat content is independent of the ⬇️ in plasma glucose Strongly associated with ⬇️ in body weight & improvement in insulin sensitivity diabetesjournals.org/care/article-a…
account_circle